行情

BLRX

BLRX

BioLine RX
NASDAQ

实时行情|Nasdaq Last Sale

1.306
+0.076
+6.15%
交易中 12:34 04/02 EDT
开盘
1.330
昨收
1.230
最高
1.330
最低
1.235
成交量
1,212
成交额
--
52周最高
6.75
52周最低
1.061
市值
1,279.66万
市盈率(TTM)
-0.5008
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测BLRX价格均价为11.33,最高价位18.00,最低价为5.00。

EPS

BLRX 新闻

更多
  • BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/12 16:42
  • biolinerx EPS beats by $2.14
  • seekingalpha · 03/12 16:06
  • BioLineRx Ltd. to Host Earnings Call
  • ACCESSWIRE · 03/12 13:00
  • BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update
  • PR Newswire · 03/12 12:00

所属板块

生物技术和医学研究
+2.13%
制药与医学研究
+1.66%

热门股票

代码
价格
涨跌幅

BLRX 简况

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.
展开

微牛提供BioLineRX Ltd.(NASDAQ-BLRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的BLRX股票新闻,以帮助您做出投资决策。